Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
- Conditions
- Tinea Pedis
- Interventions
- Drug: NAFT-600 (naftin 2 % gel)Drug: Placebo
- Registration Number
- NCT01290341
- Lead Sponsor
- Merz North America, Inc.
- Brief Summary
This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.
- Detailed Description
This study is open to males and non-pregnant females, 12 years of age and over, with clinical signs and symptoms of tinea pedis consisting of at least moderate erythema, moderate scaling, mild pruritus, a positive screening KOH, and a positive culture.Subjects will be evaluated at Day 1 (baseline), Week 2, Week 4, and Week 6 (follow-up). Adverse events, concomitant medications,and study drug compliance will be reviewed at each visit. Efficacy assessments will include KOH and culture evaluations, clinical signs/symptoms (erythema, scaling, pruritus), and Investigator's Global Assessment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 860
- Males or non-pregnant females, ≥12 years of age, of any race or sex. Females of child-bearing potential must have a negative urine pregnancy test.
- For minors (less than 18 years), the parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).
- Presence of interdigital only or both interdigital and moccasin types of tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling and mild pruritus) based on signs and symptoms in the affected area(s).
- Subjects with life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina or myocardial infarction) within the last 6 months.
- Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.
- Subjects with a known hypersensitivity to study drugs or their components.
- Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
- Uncontrolled diabetes mellitus.
- Hemodialysis or chronic ambulatory peritoneal dialysis therapy.
- Current diagnosis of immunocompromising conditions.
- Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact dermatitis.
- Severe dermatophytoses, onychomycosis (on the evaluated foot), mucocutaneous candidiasis or bacterial skin infection.
- Extremely severe tinea pedis (incapacitating).
- Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description NAFT-600 ( naftin 2 % gel) NAFT-600 (naftin 2 % gel) Topical; applied once daily for two weeks Placebo Placebo Topical; applied once daily for two weeks.
- Primary Outcome Measures
Name Time Method Complete Cure of Interdigital Tinea Pedis Visit 4/ Week 6 The primary efficacy comparison between NAFT-600 gel and placebo will be based on the percentage of subjects at Week 6 with complete cure of interdigital tinea pedis.
Complete cure is defined as negative mycology results (dermatophyte culture and KOH) and the absence of erythema, scaling, and pruritus.
- Secondary Outcome Measures
Name Time Method Effective Treatment and Mycological Cure of Interdigital Tinea Pedis at Week 6 Visit 4/ Week 6 Effective treatment of interdigital tinea pedis which is defined as negative KOH and negative dermatophyte culture and erythema, scaling, and pruritus scores of 0 or 1 (corresponding to absent and mild respectively).
Mycological cure of interdigital tinea pedis which is defined as negative KOH and negative dermatophyte culture.
Trial Locations
- Locations (22)
Research Across America
🇺🇸Dallas, Texas, United States
Clinical Research Atlanta
🇺🇸Stockbridge, Georgia, United States
Hudson Dermatology
🇺🇸Evansville, Indiana, United States
The Education and Research Foundation, Inc.
🇺🇸Lynchburg, Virginia, United States
Radiant Research, Inc.
🇺🇸Columbus, Ohio, United States
Tampa Bay Medical Research
🇺🇸Clearwater, Florida, United States
T. Joseph Raoof, MD, Inc.
🇺🇸Encino, California, United States
Madison Skin and Research, Inc
🇺🇸Madison, Wisconsin, United States
Temple University- School of Podiatric Medicine
🇺🇸Philadelphia, Pennsylvania, United States
DermResearch, Inc.
🇺🇸Austin, Texas, United States
Longmont Clinic, PC
🇺🇸Longmont, Colorado, United States
Walter K. Nahm, MD, PhD, Inc.
🇺🇸San Diego, California, United States
Radiant Research, Inc
🇺🇸Cincinnati, Ohio, United States
Academic Dermatology Associates
🇺🇸Albuquerque, New Mexico, United States
J&S Studies, Inc.
🇺🇸College Station, Texas, United States
Lake Washington Foot and Ankle Center
🇺🇸Melbourne, Florida, United States
Palmetto Clinical Trial Services, LLC
🇺🇸Simpsonville, South Carolina, United States
Colorado Medical Research Center
🇺🇸Denver, Colorado, United States
Department of Veterans Affairs
🇺🇸Minneapolis, Minnesota, United States
Endeavor Clinical Trials, PA
🇺🇸San Antonio, Texas, United States
Oregon Dermatology & Research Center
🇺🇸Portland, Oregon, United States
Progressive Clinical Research
🇺🇸San Antonio, Texas, United States